|Bid||55.29 x 1000|
|Ask||55.28 x 900|
|Day's range||54.77 - 57.59|
|52-week range||35.25 - 123.99|
|Beta (5Y monthly)||1.59|
|PE ratio (TTM)||N/A|
|Earnings date||27-Apr-2020 - 03-May-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||107.60|
PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. “Kim has been a leader and a pioneer in introducing new technologies into the healthcare system impacting the lives of countless patients during her time at Genomic Health and Genentech,” said Serge Saxonov, co-founder and CEO of 10x Genomics.
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0.00% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Exact Sciences Corporation has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health